|1.||Cohen, Jonathan C: 5 articles (02/2015 - 06/2004)|
|2.||Hobbs, Helen H: 5 articles (02/2015 - 06/2004)|
|3.||Patel, Shailendra B: 5 articles (10/2013 - 09/2004)|
|4.||Bai, Xia: 4 articles (03/2014 - 01/2011)|
|5.||Ruan, Changgeng: 3 articles (03/2014 - 01/2011)|
|6.||Wang, Zhaoyue: 3 articles (03/2014 - 01/2011)|
|7.||Wang, Gaifeng: 3 articles (03/2014 - 01/2011)|
|8.||Cao, Lijuan: 3 articles (03/2014 - 01/2011)|
|9.||Myrie, Semone B: 2 articles (05/2015 - 12/2013)|
|10.||Othman, Rgia A: 2 articles (05/2015 - 12/2013)|
05/01/2014 - "The clinical and biological characteristics of our patients, considered together with reports of cases which equally lack CVD, support the contention that the premature atherosclerosis associated with phytosterolemia in some patients may be due at least in part to mechanisms independent of elevated circulating phytosterol levels."
05/01/2014 - "Phytosterolemia is believed to be responsible for severe premature atherosclerosis. "
01/01/2011 - "The underlying mechanisms of atherogenesis in phytosterolemia, however, have not been completely elucidated. "
08/01/2010 - "Likewise, sitosterolemia is another inherited syndrome associated with premature atherosclerosis. "
01/01/2009 - "No convincing evidence is available that statin-induced phytosterolemia worsens atherosclerosis."
08/01/2014 - "The lipid panel revealed hypercholesterolemia with elevated serum plant sterol concentrations, suggesting the diagnosis of sitosterolemia. "
05/01/2014 - "Sitosterolemia should be suspected when a patient with hypercholesterolemia shows unexpectedly good response to dietary modification or bile acid sequestrant therapy."
05/01/2014 - "The clinical, biological and molecular genetic features of 5 patients with phytosterolemia and transient severe hypercholesterolemia challenge this hypothesis. "
04/01/2007 - "familiar hypercholesterolemia, sitosterolemia), but in most of the disorders the exact genetic cause remains unknown. "
08/06/2004 - "Thus, NPC1L1 may be a useful drug target for the treatment of hypercholesterolemia and sitosterolemia."
|3.||Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
01/01/2003 - "Ezetimibe plus a statin reduced LDL-C levels more than the maximum statin dose alone in a trial in patients with homozygous familial hypercholesterolemia and was effective in a placebo-controlled trial in patients with homozygous sitosterolemia. "
10/07/2004 - "Ezetimibe provides an effective therapeutic strategy for the management of homozygous familial hypercholesterolemia (HoFH) and sitosterolemia. "
11/01/2003 - "In addition, ezetimibe has been evaluated in patients with homozygous and heterozygous familial hypercholesterolemia and in those with sitosterolemia. "
06/01/2014 - "Tendinous and tuberous xanthomas are typical for autosomal dominant hypercholesterolemia, as well as for some rare conditions, such as cerebrotendinous xanthomatosis and familial β-sitosterolemia. "
12/01/2005 - "Ezetimibe is indicated in the management of hyperlipidemia, familial hypercholesterolemia, and sitosterolemia and significantly increases the percentage of patients able to reach their lipid-lowering goals."
03/01/2015 - "[Sitosterolemia in a 2 year-old child with xanthomas and hematological anomalies]."
07/03/2003 - "Phytosterolemia and xanthomatosis."
11/01/2000 - "We present a 7-year-old girl with sitosterolemia and tuberous xanthomas."
11/01/2000 - "Tuberous xanthomas in sitosterolemia."
02/01/1997 - "The clinical features of the first case of a patient with sitosterolemia and generalized eruptive xanthomatosis are described. "
04/01/1988 - "[Cerebrotendinous xanthomatosis and phytosterolemia]."
08/01/1981 - "A unique patient with coexisting cerebrotendinous xanthomatosis and beta-sitosterolemia."
07/01/2013 - "Tendon xanthomas also occur in two rare conditions, cerebrotendinous xanthomatosis and sitosterolemia, which are not easily confused with FH, can be easily differentiated with clinical history and biochemical tests. "
09/01/2001 - "However, despite these significant achievements in animal experimentation, there are no suitable animal models for several rare types of fatal dyslipidemia-associated disorders such as phytosterolemia and cerebrotendinous xanthomatosis. "
12/01/2001 - "We then analyzed by gas-liquid chromatography-mass spectrometry the oxyphytosterol concentrations in serum from patients with phytosterolemia or cerebrotendinous xanthomatosis, in a pool serum and in two lipid emulsions. "
|4.||Cholestyramine Resin (Questran)
|5.||Phytosterols (Plant Sterols)
|9.||Apolipoproteins B (ApoB)
|1.||Diet Therapy (Therapy, Diet)
|4.||Blood Component Removal (Apheresis)